Skip to Content
 

VICC toll-free number 1-877-936-8422

Childhood Cancers

The Division of Hematology and Oncology at Monroe Carell Jr. Children's Hospital at Vanderbilt includes a dedicated faculty and staff who work together as a team in the diagnosis and treatment of children with cancer or blood diseases. The division also supports a variety of clinical and research programs, a consultation service, and a fellowship training program.

Clinical Trials for Pediatric Cancers

27 Open Trials

Trial Type Protocol No. &
Open Date
Summary

Basic Science

VICCPED1544

12/14/2015

Michigan Acute Graft-versus-Host Disease International Consortium (MAGIC): A Database and Biorepository

Basic Science

COGAALL08B1

10/18/2010

Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

Basic Science

COGAALL05B1

12/01/2006

A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens

Basic Science

COGANHL04B1

09/14/2006

Rare and Cutaneous Non-Hodgkin Lymphoma Registry

Health Services Research

VICCNCPED1513

08/28/2015

An Observational, Multi-Center Study to Evaluate the Safety of Deferasirox in the Treatment of Pediatric Patients with Non-Transfusion-Dependent Iron Overload

Health Services Research

VICCPED14127

01/08/2015

Infectious Disease Outcomes in Pediatric Oncology Patients

Health Services Research

VICCREACH1447

04/16/2014

Retinoblastoma Survivor Study (RBSS)

Other

VICCPED16115

09/29/2016

Pediatric Ocular Tumor Tissue Acquisition to Study Biologic Correlates of Disease

Other

VICCPED1639

09/28/2016

Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies

Other

COGAPEC14B1

01/20/2016

The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study

Other

VICCPED0710

03/16/2007

Long Term Effects for Childhood Cancer Survivors

Other

COGALTE03N1

04/20/2005

Key Adverse Events after Childhood Cancer

Prevention

VICCPED1627

11/17/2016

Abatacept Combined with a Calcineurin Inhibitor and Methotrexate for Graft Versus Host Disease Prophylaxis

Prevention

COGALTE1621

10/03/2016

Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial

Supportive Care

VICCPED14130

07/27/2015

Impact of a PCRC-Supported Legacy Intervention in Pediatric Palliative Care

Supportive Care

VICCSAR1568

05/23/2013

Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY): A Multi-Center Randomized Controlled Study Comparing Alternative Antibiotic Regimens in Patients Undergoing Tumor Resections with Endoprosthetic Replacements

Treatment

COGADVL1322

10/31/2016

A Phase II Study of Pazopanib (GW786034, NSC# 737754) in Children, Adolescents and Young Adults with Refractory Solid Tumors

Treatment

COGARST1431

08/18/2016

A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)

Treatment

COGADVL1522

08/02/2016

A Phase 2 Study of IMGN901 (Lorvotuzumab Mertansine; IND# 126953, NSC# 783609) in Children with Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor (MPNST) and Synovial Sarcoma

Treatment

VICCPED1537

04/28/2016

T2014-001 A Phase I Trial of Temsirolimus (CC-779, Pfizer, Inc.) in Combination with Etoposide and Cyclophosphamide in Children with Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma

Treatment

COGAAML1331

04/28/2016

A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid

Treatment

COGAOST1321

04/07/2016

Phase 2 Study of Denosumab (IND# 127430, NSC# 744010), a RANK Ligand Antibody, for Recurrent or Refractory Osteosarcoma

Treatment

COGAALL1331

02/01/2016

Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)

Treatment

VICCPED1489

01/07/2016

Molecular-Guided Therapy for the Treatment of Patients with Relapsed and Refractory Childhood Cancers

Treatment

COGAALL1231

05/13/2015

A Phase III Randomized Trial Investigating Bortezomib NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)

Treatment

COGANBL1232

08/20/2014

Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma

Treatment

VICCPED1249

08/06/2012

An Open Label, Expanded Access Protocol using 131I-Metaiodobenzylguanidine (131I-MIBG) Therapy in Patients with Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma